Sildava (Sildenafil Citrate) is commonly used across conditions presenting with acute episodes and applied across domains where additional symptomatic support is needed. The medication is used when supportive symptom management is appropriate in two main therapeutic areas. It is applied in situations involving certain distressing symptoms across two distinct condition categories: Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH).

For adult males, Sildava is used for managing symptoms of inability to achieve or maintain an adequate erection, offering symptomatic relief that may assist with maintaining functional stability for sexual activity. For patients, including children, with PAH, the medication is applied in addressing shortness of breath and fatigue. It provides support that helps ease the overall symptom burden, particularly when physical activity is limited.

“It is applied in scenarios where additional management of discomfort is required, contributing to improved comfort during symptomatic periods.”

Quick Fact: Relief for Functional Strain
Sildava is relevant when symptoms of exercise intolerance (in PAH) or erectile difficulties (in ED) create a noticeable physiological strain on daily activities and intimate health.

Regulatory References

1. Sildenafil: MedlinePlus Drug Information

The official eligibility for Sildava (Sildenafil Citrate) is defined by strict regulatory categories, including absolute prohibitions and conditional use. The medicine is primarily allowed for adults (18 and older). Pediatric use is restricted to the treatment of Pulmonary Arterial Hypertension (PAH) in patients 1 to 17 years old, though chronic use is not recommended due to an FDA-labeled warning regarding increased mortality with higher doses. Use for Erectile Dysfunction (ED) is not indicated in females or pediatric patients.

Populations for Whom Use is Contraindicated

Category	Eligibility Status (Regulatory)
Concurrent Medications	Patients taking any form of organic nitrates or guanylate cyclase stimulators (e.g., riociguat).
Hypersensitivity	Patients with known allergy to Sildenafil or any component of the formulation.
Clinical Status	Patients with recent stroke or myocardial infarction, severe hypotension (BP <90/50 mmHg), or severe hepatic impairment.
Ocular History	Patients with a history of vision loss due to Non-arteritic anterior ischaemic optic neuropathy (NAION).

Eligibility is limited in patients with severe renal or hepatic impairment, who may require a lower initial dose for ED use. Caution is required for patients with anatomical penile deformities, conditions predisposing to priapism (like sickle cell disease), and those with certain cardiac conditions where sexual activity is inadvisable.

Interactions with other medicines and products

Sildava (Sildenafil Citrate) has documented interaction patterns strictly defined in regulatory labeling, which establish absolute prohibitions and requirements for exposure management.

Contraindicated Combinations

Co-administration with all forms of Nitrates or Nitric Oxide Donors is strictly contraindicated due to the severe risk of potentiating hypotensive effects. The use of Guanylate Cyclase (sGC) Stimulators (such as Riociguat) is also prohibited because of the potential for symptomatic hypotension. Co-administration with other Phosphodiesterase Type 5 (PDE5) Inhibitors is not recommended.

Exposure Modification and Timing

Sildava clearance is reduced by potent CYP3A4 inhibitors (e.g., Ritonavir, Saquinavir), resulting in significantly increased plasma concentrations. For example, the use with Ritonavir is documented to increase Sildenafil exposure by up to 11-fold, necessitating a maximum dose restriction of 25 mg within a 48-hour period.

Pharmacodynamic interactions with alpha-blockers (e.g., Doxazosin) create an additive effect that may cause symptomatic hypotension, with the highest risk documented within 4 hours of administration. Sildenafil clearance is officially noted as reduced in individuals with hepatic impairment or severe renal impairment. Furthermore, a heavy, high-fat meal can delay the onset of activity.

The Mechanism of Sildava

Sildava's mechanism centers on the selective inhibition of the enzyme Phosphodiesterase Type 5 (PDE5), which is concentrated within the smooth muscle cells of the pulmonary and genital vasculature. By acting as a competitive inhibitor, Sildava blocks PDE5 from catalyzing the breakdown of the second messenger molecule, cyclic Guanosine Monophosphate (cGMP). This molecular interaction leads to the sustained, elevated concentration of cGMP within the cell.

This preservation of cGMP amplifies the signaling effect of naturally released Nitric Oxide (NO). The resulting elevated cGMP activates Protein Kinase G (PKG), triggering a molecular cascade that reduces intracellular calcium ( Ca^2+) concentration. Lowering Ca^2+ promotes smooth muscle relaxation, causing functional vasodilation (arterial widening). This systemic adjustment results in an increase in regional blood flow. The drug's action is fundamentally dependent on the prior physiological release of NO; it modulates, but does not initiate, the relaxation pathway.

Sildava (Sildenafil Citrate) is administered through two official routes: oral consumption, available in various tablet and suspension forms, and intravenous (IV) injection. The appropriate dose, frequency, and duration are determined by the condition being addressed.

Oral Administration for Erectile Dysfunction

For the management of Erectile Dysfunction (ED), Sildava is used on an as-needed basis, with a maximum frequency of once per day. The recommended initial dose is 50 mg, which may be adjusted to a range between 25 mg and 100 mg. This single dose should be taken approximately one hour before activity, though the drug may be administered from 30 minutes to four hours prior. The timing can be influenced by meals, as consumption alongside a high-fat meal may delay the onset of action. A reduced starting dose, typically 25 mg, is considered for older adults, as well as for patients with severe hepatic or renal impairment.

Administration for Pulmonary Arterial Hypertension

Use of Sildava for Pulmonary Arterial Hypertension (PAH) is characterized as a long-term maintenance regimen. The standard oral dose is 20 mg, administered three times a day (TID). Doses must be spaced approximately 4 to 6 hours apart to maintain a consistent dosing interval. Patients temporarily unable to take oral therapy may receive the drug via intravenous injection at a dose of 10 mg TID. The official oral suspension form requires precise reconstitution with water and must be measured using the provided calibrated oral syringe prior to each administration. If a scheduled PAH dose is missed, the standard approach is to skip the missed dose if the next dose is due soon, and never to take two doses simultaneously.

Research evidence / Overview of studies for Sildava

This overview summarizes the formal research, primarily randomized controlled trials (RCTs) and systematic reviews, that has been conducted on Sildava for the conditions it has been studied for. The findings described here reflect group patterns observed in the studies and do not provide individual predictions. Research is focused on what was studied and what remains uncertain in the evidence landscape.

---

Evidence for use in Erectile Dysfunction (ED)

The primary research for Sildava in adult men with Erectile Dysfunction was evaluated in multiple short-term, double-blind, placebo-controlled clinical trials. These studies are considered the primary source of clinical evidence and were used to explore the condition in the study context. Researchers focused on outcomes reflecting daily functioning and used standardized questionnaires to track changes in patient-reported experiences related to erectile difficulties.

Studies reported measurements related to patient-reported scores when compared against placebo. Trials also monitored success rates, which involved tracking how often study participants logged attempts at sexual activity during the observed time intervals. Findings describe patterns observed in the studies related to these short-term functional outcomes.

---

Evidence for use in Pulmonary Arterial Hypertension (PAH)

For patients with Pulmonary Arterial Hypertension (PAH), Sildava was studied for its use in relation to functional capacity, which research monitored to reflect daily functioning. The main evidence comes from short-term RCTs that measured changes in the distance patients could walk during a specified time (the 6-Minute Walk Distance, or 6MWD) and tracked systemic outcomes, such as time to clinical worsening (a composite measure of disease progression or hospitalization).

An area of specific uncertainty exists in the pediatric research. Sildava was evaluated in specific trials for children and adolescents with PAH. Subsequent long-term follow-up described an unexpected pattern that resulted in specific scientific questions and cautions regarding the use of higher doses in children. Certainty remains low regarding the optimal long-term management and safety profile for all pediatric PAH populations.

---

Limitations and Research Gaps

Reviewing the limitations and evidence gaps is important for contextualizing research findings. Evidence quality varies across studies, and the majority of high-quality RCTs focused on short-term outcomes, meaning long-term effects are not fully established for either condition. Furthermore, comparative evidence is lacking from trials directly contrasting Sildava against other licensed treatments. All results apply only to the populations studied and findings describe group patterns, not personal outcomes.

Key Studies & References

1. Sildenafil in Infants and Children (Referenced for pediatric use and long-term concerns).

Common questions about Sildava (FAQ)

---

Q: Can I drink alcohol while taking this medicine?

Official regulatory information states that drinking alcohol while taking Sildava should be avoided. Combining Sildava with alcohol can increase the risk of certain side effects, such as heightened dizziness, drowsiness, and difficulty focusing. This is because both substances can affect your central nervous system.

---

Q: Does it make you sleepy?

Yes, regulatory documents report that dizziness and somnolence, which is a medical term for sleepiness or drowsiness, are very common side effects of Sildava. Due to the potential for impaired alertness, official labeling includes warnings about using caution when driving or operating machinery if these side effects occur.

---

Q: What should I do if I am pregnant or breastfeeding?

According to the official product information, Sildava may cause harm to a developing fetus, and regulatory agencies do not recommend breastfeeding while using this medicine. It is also stated that women who are able to become pregnant should use effective birth control while taking Sildava. It is important that any patient who is pregnant, planning pregnancy, or breastfeeding consults with their healthcare provider.

---

Q: How should I store this medicine?

Regulatory documents indicate that Sildava capsules should be stored at room temperature, typically between 68 F to 77 F (20 C to 25 C). To maintain the medicine's effectiveness and safety, it should be kept in its original package and stored out of the sight and reach of children.

---

Q: Is it safe long-term?

Official regulatory agencies have addressed risks associated with long-term use, noting concerns such as the potential for dependence and the need for gradual discontinuation rather than suddenly stopping the medicine. The labeling also highlights the risk of serious breathing problems, especially when Sildava is taken alongside other medicines that depress the central nervous system or if the patient has existing breathing difficulties. The clinical decision regarding long-term use is based on an assessment by the prescribing healthcare provider.

---

Q: Can children 2 years old use it?

The approved uses for Sildava are generally for adults and, for some specific conditions, adolescents aged 17 years and older. Regulatory agencies have not authorized or recommended the use of this medicine in young children for most indications. Official product labeling indicates that use in younger pediatric patients is generally not established for many of the approved indications.

How to Store and Dispose of Sildava

Sildava (Sildenafil) must be stored under specific environmental conditions, and disposal must follow regulatory guidelines.

---

Storage Requirements

• Tablets and Dry Powder: Store at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). Brief temperature excursions up to 30 C (86 F) are typically permitted.
• Reconstituted Oral Suspension: After mixing, store at or below 30 C (86 F). Do not freeze the liquid suspension.
• Stability: The reconstituted suspension must be discarded after 60 days from the date of mixing.
• Child Safety: Keep the medicine out of the sight and reach of children at all times.

---

Disposal

Unused or expired Sildava must be disposed of in accordance with local requirements. It should not be disposed of via wastewater or routine household waste.